

J. Turgeon, B. Pharm., Ph.D.
Publications 2013-2019

CURRICULUM VITAE

Chief Scientific Officer
Tabula Rasa HealthCare (TRHC)
Chief Executive Officer
TRHC (Scientific Precision Pharmacotherapy Research & Development Institute)
13485 Veteran's Way, Suite 400
Orlando, Florida, 32827
Phone: 856-938-8793

Jacques Turgeon, B.Pharm., Ph.D.
jturgeon@trhc.com

Publications (2013-2019)

A) Original Manuscripts:

- 116.** Skrobik, Y., Léger, C., Cossette, M., Michaud, V., Turgeon, J. **Predisposing factors to coma and delirium : Fentanyl and midazolam exposure, CYP3A5, ABCB1 and ABCG2 genetic polymorphisms, and inflammatory factors.** Critical Care Med 2013;41:999-1008.
- 117.** De Denus, S., Letarte, N., Hurlimann, T., Lambert, J-P, Lavoie, A., Robb, L., Sheehan, N., Turgeon, J., Vadnais, B. **An Evaluation of Pharmacists' Expectations towards Pharmacogenomics,** Pharmacogenomics, 2013, 14(2), 165-175.
- 118.** Michaud, V., Turgeon, J. **Domperidone and sudden cardiac death: how much longer should we wait ?** J of Cardiovascular Pharmacol, 2013 Mar;61(3):215-7.
- 119.** Doan, J., Zakrzewski-Jakubiak, H., Roy, J., Turgeon, J., Tannenbaum, C. **Prevalence and risk of cytochrome P450 drug-drug interactions in older hospitalized patients with polypharmacy,** Ann of Pharmacotherapy, 2013 March, Vol 47: 324-332.
- 120.** Madadi, P, Amstutz, U, Rieder, M, Ito, S, Fung, V, Hwang, S, Turgeon, J., Michaud, V, Koren, G, Carleton, BC; CPNDS Clinical Recommendations Group. **Clinical practice guideline: Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.** J Popul Ther Clin Pharmacol. 2013;20(3):e369-96. Epub 2013 Nov 6.
- 121.** Dubé, M.P., Zetler, R., Barhdadi, A., Brown, A., Mongrain, I., Normand, V., Laplante, N., Asselin, G., Feroz Zada, Y., Provost, S., deDenus, S., Réhaume, E., Turgeon, J., Phillips, M., Tardif, J.C. **CKM and LILRB5 are associated with serum levels of creatine kinase in statin users.** Circulation: Cardiovascular Genetics, 2014; 7: 880-886.
- 122.** Lu, J., Michaud, V., Guilarte Moya Liliam, G., Gaudette, F., Leung, Yat Hei, Turgeon, J. **Effects of β -blockers and tricyclic antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2).** J Pharmacol Exp Ther. 2015; 352: 552-558.

123. Shaw, K., Amstutz, U., Kim, R., Lesko, L.J., Turgeon, J., Michaud V., Hwang, S, Ito, S., Carleton, B.C., and the CPNDS clinical recommendation group¹⁰, **Clinical Practice Recommendations on Genetic Testing of *CYP2C9* and *VKORC1* Variants in Warfarin Therapy.** Therapeutic Drug Monitoring. 2015; 37: 428-436.
124. Gaudette, F., Sirhan-Daneau, A., St-Onge, M., Turgeon, J., Michaud V. **Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.** Journal of Chromatography B. 2016; 1008:174-80.
125. Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J., Michaud V. **Evaluation of limited sampling methods for oral busulfan pharmacokinetic monitoring in adult patients undergoing hematopoietic stem cell transplantation.** Ther Drug Monit. 2016; 38:414-418.
126. Turgeon J., Michaud V. **Clinical decision support systems: Great promises for better management of patients' drug therapy.** Expert Opin Drug Metab Toxicol. 2016; 12:993-995.
127. Huguet, J., Lu, J., Gaudette, F., Chiasson, J.-L., Hamet, P., Michaud, V., Turgeon, J. **No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.** Eur J. Clinical Pharmacology. 2016; 72(8): 925-931.
128. Grangeon A., Gravel S, Gaudette F., Turgeon, J., Michaud V., **Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human.** J. Chromatogr. B 2017;1040:144-158.
129. Bain KT, Knowlton CH, Turgeon J. **Medication Risk Mitigation: Coordinating and Collaborating with Health Care Systems, Universities, and Researchers to Facilitate the Design and Execution of Practice-Based Research.** Clin Geriatr Med. 2017 May;33(2): 257-281.
130. Maximos S, Chamoun M, Gravel S, Turgeon J., Michaud V. **Tissue Specific Modulation of *cyp2c* and *cyp3a* mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.** Pharmaceutics. 2017 Sep 26;9(4). pii: E40.
131. Turgeon J., Michaud V, Steffen L. **The Dangers of Polypharmacy in Elderly Patients.** JAMA Intern Med. 2017 Oct 1; 177 (10):1544
132. Leung YH, Turgeon J., Michaud V. **Study of Statin-and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells.** Pharmaceutics. 2017 Oct 10; 9(4). pii: E42.
133. Schwartz Ej, Turgeon J., Patel J, Patel P, Shah H, Issa AM, Knowlton OV, Knowlton CH, Bain KT. **Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care.** J Am Board Fam Med. 2017 Nov-Dec; 30 (6): 701-714.
134. Leung YH, Belanger F, Lu J, Turgeon J, Michaud V. **Effects of a series of acidic drugs on L-lactic acid transport by the monocarboxylate transporters MCT1 and MCT4.** Curr Pharm Biotechnol. 2017;18:1141-1150.
135. Gravel S, Chiasson JL, Dallaire S, Turgeon J., Michaud V. **Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.** BMJ Open. 2018 Feb 8;8(2):e020922.

136. Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. *Calin Cardiol* 2018;41:576-585.
137. Cicali B, Michaud V, Knowlton CH, Turgeon J. **Application of a novel medication-related risk stratification strategy to a self-funded employer population.** *Benefits Quarterly* 2018; Second Quarter:49-55.
138. Bain KT, Schwartz EJ, Knowlton OV, Knowlton CK, Turgeon J. **Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE).** *J Am Pharm Assoc* 2018;58:281-289.
139. de Denus S, Dubé MP, Fouodjio R, Huynh T, LeBlanc MH, Lepage S, Sheppard R, Giannetti N, Lavoie J, Mansour A, Provost S, Normand V, Mongrain I, Langlois M, O'Meara E, Ducharme A, Racine N, Guertin MC, Turgeon J, Phillips MS, Rouleau JL, Tardif JC, White M; CANDIID II investigators. **A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.** *Pharmacogenomics* 2018;19:599-612.
140. Huguet J, Gaudette F, Michaud V, Turgeon J. **Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes.** *Xenobiotica*. 2019;49:187-199.

B) Abstracts:

327. Huguet, J., Gaudette, F., Michaud, V., Turgeon, J. **A probe drug cocktail to study CYP2C8, 1A1 and 2D6 in the human heart.** *Clinical Pharmacol & Ther* 2013, 93 (Suppl 1):60.
328. Leung, Y., Lu, J., Bélanger F., Turgeon, J, Michaud, V. **Drug-transporter interactions : inhibition of MCT1 and MCT4 by statins and other acidic drugs,** *Clinical Pharmacol & Ther* 2013, 93(Suppl 1):60.
329. Lu, J., Guilarte Moya, L.G., Leung, Y., Gaudette, F., Turgeon, J. **Tricyclic drugs inhibit the uptake of rosuvastatin through the OATP1A2 transporter,** *Clinical Pharmacol & Ther* 2013, 93(Suppl 1):30.
330. Yang, X., Gaudette, F., Guilarte, L.G., Armstrong, C., Turgeon, J. **mRNA levels of cytochrome P450s in endometrial cancer cells.** *Clinical Pharmacol & Ther* 2013, 93(Suppl 1):98.
331. Lu, J., Guilarte Moya, L.G., Leung, Y., Gaudette, F., Turgeon, J. **Tricyclic compounds inhibit the OATP1A2 transporter,** CSPT 2013, Boston, MA.
332. Huguet J., Gaudette F., Michaud V., Turgeon J. **Functional activity in human heart expressing CYP1A1,** CSPT 2013, Boston, MA.
333. Leung, Y., Lu, J., Papillon, M., Bélanger, F., Turgeon, J, Michaud, V. **The role of MCT1 and MCT4 in drug-induced muscle disorders,** CSPT 2013, Boston, MA.
334. Martel, D., Sheehan, N.L., Tremblay, C.L., Turgeon, J, Tseng, A., Phaneuf, D., Noël, G.E., Thibeault, D., Labbé, I. **Pharmacokinetic interaction of the direct acting antiviral agent beceprevir with maraviroc in healthy volunteers,** 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, the Netherlands.

335. Leung, Y., Lu, J., Bélanger, F., Turgeon, J., Michaud, V. **Rôle des transporteurs MCT1 et MCT4 dans les désordres musculaires induits par les statines**, CRCQ 2013, p. 203.
336. Leung, Y., Papillon, M., Turgeon, J., Michaud, V. **Statin-specific transport by MCT1 and MCT4**, Clinical Pharmacol & Ther 2014, 95(Suppl 1):29.
337. Huguet, J., Gaudette, F., Bélanger, F., Michaud, V., Turgeon, J. **Intersubject variability CYP212 activity in human heart microsomes**. Clinical Pharmacol & Ther 2014, 95(Suppl 1):30.
338. Huguet, J., Sharma, S., Gaudette, F., Bélanger, F., Fulton, S., Turgeon, J., Michaud, V. **CYP450 mediated metabolism in extra-hepatic tissues**, Clinical Pharmacol & Ther 2014, 95(Suppl 1):30.
339. Lu, J., Guilarte Moya, L., Leung, Y., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Inhibition of the OATP1A2 transporter by tricyclic compounds**, Clinical Pharmacol & Ther 2014, 95(Suppl 1):70.
340. Gravel, S., Huguet, J., Rousseau, E., Gaudette, F., Turgeon, J., Michaud, V. **CYP450 mediated drug metabolism in human lung tissue**. 19th North American ISSX meeting, San Francisco, October 2014.
341. Lu, J., Grangeon, A., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Effects of tricyclic compounds on almotriptan transport through OATP1A2**. 19th North American ISSX meeting, San Francisco, October 2014.
342. Huguet, J., Bélanger, F., Michaud, V., Turgeon, J. **Impact of CYP2J2*7 on drug metabolism in the human heart**. 19th North American ISSX meeting, San Francisco, October 2014.
343. Pelletier, R., Gravel, S., Huguet, J., Turgeon, J., Michaud, V. **Metabolism of olanzapine in human heart microsomes**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PII-018.
344. Gravel, S., Huguet, J., Gaudette, F., Turgeon, J., Michaud, V. **Iloperidone metabolism in human hearts**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PII-015.
345. Ghazal, N., Yeung, Y., Ngan, Z., Wang, H., El-Sakkary, M., Bélanger, F., Sheehan, N., Lebouché, B., Turgeon, J., Labbé, L., Michaud, V. **Comparison of drug-transporter mRNA expression levels in PBMC from HIV-infected patients with and without diabetes**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PI-031.
346. Lu, J., Grangeon, A., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Effects of tricyclic compounds on naratriptan transport through OATP1A2**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PI-025
347. Leung, Y., Turgeon, J., Michaud, V. **Statin inhibition of lactic acid transport in human skeletal muscle**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PII-012.
348. Pilote, S., Kamaliza, J., Turgeon, J., Michaud, V., Simard, C., Drolet, B. **The effect of intracellular methadone on hERG current is modulated by the coexpression of the CYP450 isozyme 2B6**. Annual meeting American Society for Pharmacology and Therapeutics, New Orleans, 2015, :PII-014

349. Maximos, S., Leung, Y., Gravel, S., Bélanger, F., Gaudette, F., Turgeon, J., Michaud, V. **Hepatic and extra-hepatic CYP450s activity modulation in C57BL/6 mice fed a high-fat diet.** 20th North American International Society of the Study of Xenobiotics, Orlando FL, 2015: P208.
350. Lu, J., Gaudette, F., Keiser, M., Michaud, V., Turgeon, J. **Effects of tricyclic compounds on zolmitriptan transport through OATP1A2.** North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P250.
351. Grangeon, A., Gaudette, F., Turgeon, J., Michaud, V. **Highly sensitive LC-MS/MS methods for the in vivo assessment of human CYP450 activities using small doses of probe-drugs.** North American meeting of the International Society for the Study of Xenobiotics, Orlando FL, 2015: P3.
352. Gravel, S., Huguét, J., Gaudette, F., Turgeon, J., Michaud, V. **Iloperidone metabolism in human heart micosomal and cytosolic fractions.** North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: PII-136.
353. Leung, Y., Turgeon, J., Michaud, V. **Inhibition of lactic acid efflux by atorvastatin in human skeletal muscle cells.** North American meeting of the International Society for the Study of Xenobiotics, Orlando, 2015: P259.
354. Gravel, S., Grangeon, A., Gaudette, F., Chiasson, J.L., Dallaire, S., Langelier, H., Turgeon, J., Michaud, V. **Type 2 diabetes modulates CYP450 metabolic activities.** 10th MDRC annual meeting. Montreal, Quebec, 2016. Oral poster (ranked in the top 10%).
355. Gravel, S., Grangeon, A., Gaudette, F., Chiasson J.L., Dallaire, S., Langelier, H., Turgeon, J., Michaud, V. **Type 2 diabetes modulates CYP450 metabolic activities; an important factor of variability in drug response.** American Society for Pharmacology and Therapeutics meeting, San Diego 2016. Late-breaking abstract.
356. Steffen, L.E., Knowlton, C.H., Turgeon, J. **Development of a drug-specific Long QT-JT Index for prediction of drug-induced QT Prolongation.** American Heart Association Annual Meeting Scientific Sessions. Circulation 2016;134:A15939.
357. Steffen, L.E., Knowlton, C.H., Turgeon, J. **Risk Identification of drug-induced Long QT Syndrome using a Patient-Specific Long QT-JT Risk Score.** American Heart Association Annual Meeting Scientific Sessions. Circulation;134:A16114.
358. Gravel, S., Grangeon, A., Gaudette, F., Belanger, F., Chiasson, J.L., Dallaire, S., Langelier, H., Turgeon, J., Michaudm V. **Effect du diabete de type 2 sur le metabolisme des medicaments par les Cytochromes P450.** Annual scientific meeting of Cardiometabolic Health, Diabetes and Obesity Research Network and COLosSUS Congress. Magog-Oford, Quebec, 2017. #51.
359. Cicali, B., Badea, G., Steffen, L., Bain, K.T., Schwartz, E., Knowlton, C.H., Turgeon J. **The application of a novel medication risk stratification tool to identify high risk patients within a large population.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S60.
360. Cicali, B., Badea, G., Bain, K.T., Knowlton, C.H., Turgeon J. **Visualization technique for FAERS-based adverse event prediction.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S25.
361. Steffen, L.E., Badea, G., Cicali, B., Knowlton, C.H., Turgeon, J. **Medication-Specific Long QT-JT Index And Patient-Specific Long QT-JT Score For Assessing Risk Of Torsade De Pointes:**

- Validation In An Ambulatory Population.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S48
362. Schwartz, E.J., Patel, J., Patel, P., Shah, H., Issa, A.M., Turgeon, J., Knowlton, O.V., Knowlton, C.H., Bain, K.T. **Implementing an enhanced Standardized medication therapy management approach within a primary care setting.** American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Clin Pharmacol Ther 2017;101:S45.
363. Grangeon, A., Clermont, V., Barama, A., Gaudette, F., Turgeon, J., Michaud, V. **Simultaneous absolute protein quantification method of 14 CYP450s in human intestine by mass-spectrometry-based targeted proteomics.** American Society for Pharmacology and Therapeutics meeting. Clin Pharmacol Ther 2017;101:S66.
364. Leung, Y., Turgeon, J., Michaud, V. **Loratadine, a potent inhibitor of lactic acid transporters MCT1 and MCT4 in human skeletal muscle cells.** American Society for Pharmacology and Therapeutics meeting. American Society for Pharmacology and Therapeutics meeting. Clin Pharmacol Ther 2017;101:S35.
365. Gravel, S., Chiasson, J.L., Dallaire, S., Langelier, H., Grangeon, A., Gaudette, F., Belanger, F., Turgeon, J., Michaud, V. **Influence of type 2 diabetes on cytochromes P450 mediated drug metabolism.** American Society for Pharmacology and Therapeutics meeting. (within the top 20% of abstracts). Clin Pharmacol Ther 2017;101:S30
366. Gravel S, Panzini B, Chiasson JL, Gaudette F, Grangeon A, Turgeon J, Michaud V. **Effects of type 2 diabetes on duodenal CYP450 activities.** American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PT-011 & PWIII-004. (*Presidential Trainee Award*)
367. Michaud V, Cicali B, Verzicco J, Knowlton CH, Turgeon J. **Yearly medical expenditure in patients treated with CYP2D6-dependent opioids and impact of concomitant treatment with CYP2D6 substrate or inhibitor drugs.** American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-095.
368. Cicali B, Verzicco J, Knowlton CH, Turgeon J, Michaud V. **Increased risk medication related problems due to concomitant administration of CYP2D6-dependent opioids and CYP2D6 interacting drugs.** American Society for Pharmacology and Therapeutics meeting, Orlando FL, March 2018: PII-032.
369. Michaud V, Turgeon J. **Pain management pharmacotherapy in the context of polypharmacy and drug-drug interactions.** Global Pain Conference. Florence, Italy, August 2018.
370. Turgeon J, Michaud V. **Les tests pharmacogénomiques: le rôle des pharmaciens et des médecins.** International Congress on Personalized Health Care. September 2018.
371. Turgeon J, Michaud V. **The need for clinical decision support systems for the management of patients with polypharmacy.** International Congress on Personalized Health Care. September 2018.
372. Michaud V, Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J. **Impact of GSTA1 polymorphisms on the oral clearance of busulfan in adult patients undergoing hematopoietic stem cell transplantation.** International Congress of Personalized Health Care 2nd edition. Montreal, Canada, September 2018. Oral presentation (09/25/2018).

Accepted abstracts

- 373.** Tran M, Pronovost B, Bouchard P, Bilodeau S, Alain K, Vadnais B, Franco M, Turgeon J, Michaud V. Influence of GSTA1 Polymorphisms On **The Oral Clearance Of Busulfan Using Limited Sampling Methods In Adult Patients Undergoing Hematopoietic Stem Cell Transplantation**. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019. *Selected for the the Special Poster Session: Pharmacogenomics and for the Presidential Trainee Award.*
- 374.** Gravel S, Gaudette F, Chiasson JL, Turgeon J, Michaud V. **Use of 4 β -hydroxycholesterol plasma concentration as an endogenous biomarker of CYP3A activity: Clinical validation in patients with type 2 diabetes**. American Society for Pharmacology and Therapeutics meeting, Washington DC, March 2019.